You are here:
Xeljanz
300 - 400
Market share is generally not included unless otherwise stated.
7,787,500.00
This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.
There is currently nothing known about off label use.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines